265 related articles for article (PubMed ID: 18790747)
1. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.
Wilson C; Wilson T; Johnston PG; Longley DB; Waugh DJ
Mol Cancer Ther; 2008 Sep; 7(9):2649-61. PubMed ID: 18790747
[TBL] [Abstract][Full Text] [Related]
2. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.
Raclaw KA; Heemers HV; Kidd EM; Dehm SM; Tindall DJ
Prostate; 2008 Nov; 68(15):1696-706. PubMed ID: 18726983
[TBL] [Abstract][Full Text] [Related]
3. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Cornforth AN; Davis JS; Khanifar E; Nastiuk KL; Krolewski JJ
Oncogene; 2008 Jul; 27(32):4422-33. PubMed ID: 18391984
[TBL] [Abstract][Full Text] [Related]
4. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
5. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
[TBL] [Abstract][Full Text] [Related]
6. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde.
Kim HB; Kim MJ; Kim DY; Lee JW; Bae JH; Kim DW; Kang CD; Kim SH
Mol Cancer; 2011 Apr; 10():46. PubMed ID: 21513580
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
El-Zawahry A; McKillop J; Voelkel-Johnson C
BMC Cancer; 2005 Jan; 5():2. PubMed ID: 15638938
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L).
Min KJ; Seo BR; Bae YC; Yoo YH; Kwon TK
Cell Death Dis; 2014 Feb; 5(2):e1063. PubMed ID: 24556678
[TBL] [Abstract][Full Text] [Related]
11. Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis.
Giampietri C; Petrungaro S; Padula F; D'Alessio A; Marini ES; Facchiano A; Filippini A; Ziparo E
Apoptosis; 2012 Nov; 17(11):1210-22. PubMed ID: 22923157
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling.
Kaminskyy VO; Surova OV; Piskunova T; Zborovskaya IB; Tchevkina EM; Andera L; Zhivotovsky B
Cell Death Dis; 2013 Mar; 4(3):e522. PubMed ID: 23470529
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression.
Kelly MM; Hoel BD; Voelkel-Johnson C
Cancer Biol Ther; 2002; 1(5):520-7. PubMed ID: 12496481
[TBL] [Abstract][Full Text] [Related]
14. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M
J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925
[TBL] [Abstract][Full Text] [Related]
15. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Song JH; Kandasamy K; Kraft AS
J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP.
Seo BR; Min KJ; Woo SM; Choe M; Choi KS; Lee YK; Yoon G; Kwon TK
Antioxid Redox Signal; 2017 Aug; 27(4):215-233. PubMed ID: 27927016
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin.
Jani TS; DeVecchio J; Mazumdar T; Agyeman A; Houghton JA
J Biol Chem; 2010 Jun; 285(25):19162-72. PubMed ID: 20424169
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
19. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.
Zhang X; Zhang L; Yang H; Huang X; Otu H; Libermann TA; DeWolf WC; Khosravi-Far R; Olumi AF
Cancer Res; 2007 Oct; 67(19):9425-34. PubMed ID: 17909052
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of RIP and c-FLIP in preventing liver cancer cell apoptosis induced by TRAIL.
Sun J; Luo H; Nie W; Xu X; Miao X; Huang F; Wu H; Jin X
Int J Clin Exp Pathol; 2015; 8(6):6519-25. PubMed ID: 26261530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
